Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2008 Dec;7(12):3816–3824. doi: 10.1158/1535-7163.MCT-08-0558

Figure 1. FASN inhibitors combine with bortezomib to increase cell death.

Figure 1

Clonogenic survival assays were performed on PC-3 (A) and DU145 (B) cells. Cells were treated with the indicated concentrations of bortezomib in the presence of DMSO, C75 (10 µg/ml) or orlistat (25 µmol/L) for 16 hours. Clonogenic survival was determined relative to vehicle-treated controls. Statistical significance was determined by two tailed student’s t test of cells treated with the combination of FASN inhibitors and bortezomib compared to cells treated with FASN inhibitors alone (P ≤ 0.005). C, PC-3 cells treated with bortezomib (5 nmol/L), orlistat (25 µmol/L), C75 (10 µg/ml), or the combination of FASN inhibitors and bortezomib for 18 hours and collected for immunoblot analysis using antibodies specific for cleaved PARP, cleaved caspase 3, and total eIF2α. Images represent cropped immunoblots. Full length scans available in supplementary data figure 1.